---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-009865"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2021-08-03T23:59:59+00:00"
generated_at: "2026-06-29T23:40:17.332809+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte reports Q2 2021 product revenue $696M (+17% YoY); GAAP net income $149M vs $290M prior year

## Summary
- Jakafi net product revenues $529M (+12% YoY); total product and royalty revenues $696M (+17%).
- Non-GAAP diluted EPS $0.80 vs $1.24 prior year; GAAP net income $149M down from $290M.
- Positive CHMP opinion for tafasitamab in relapsed/refractory DLBCL; Phase 3 vitiligo trials met endpoints.
- Updated 2021 guidance: Jakafi revenue tightened to $2,125-$2,170M; SG&A reduced to $725-$755M.
- Retifanlimab BLA received FDA complete response letter; MAA still under EMA review.

## SEC filing metadata
- accession: 0001558370-21-009865
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2021-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000155837021009865/0001558370-21-009865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000155837021009865/incy-20210803x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-009865
- JSON: https://secwatch.observer/filing/0001558370-21-009865.json
- Plain text: https://secwatch.observer/filing/0001558370-21-009865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.